Quantitative exercise echocardiography in normals: Temporal changes in regional wall thickening after exercise  by Ciniglio, Ricardo et al.
314A ABSTRACTS JACC Vol. 
17, No. 2 
February 1991:334A 
QUANTITATIVE EXERCISE ECHOCARDIOGRAPHY IN 
NORMALS: TEMPORAL CHANGES IN REGIONAL WALL 
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I, ConcllLsia_n: Maximal wall thic ening occurs within 2 minutes 
of peak exercise and returns to normal after 5 minutes. The 
lower end of the normal ranges (end-systolic thickness greater 
than 1.1 cm and/or percent systolic thickenin 
B 45%) may be useful in determining a norma 
greater than 
regional wall 
thickening response to exercise. 
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Although thrombolytic therapy benefits clinical 
outcome after acute myocardial infarction, the 
relationship between vessel patency and post- 
infarct LV remodeling is less understood. Two 
dimensional echocardiography was performed 
within 48 hrs and 3 months in 30 pts treated 
with intravenous thrombolysis for their first 
myocardial infarction. Using a previously 
validated method the 3 dimensional LV total 
endocardial surface area (WA) and the extent of 
abnormal wall motion (%AWM) were quantitated. 
Coronary angiography performed at a mean of 5 
days after thrombolytic therapy was used to 
divide pts into those with a patent (Group A, 
n=20), or those with an occluded (Group 8, n--lo) 
infarct-related artery. ESA index 
(ESA,=ESA/BSA:cmz/mz) , OAWM, and A%AWM (mean?SD) 
ared between and within the groups. 
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patent infarct-related artery 
'ion is associated with 
regional LV wall function and 
dilatation. 
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Clinical data on 6077 high dose (up to 0.84 mg/Kg over 10’) 
dipyridamole-echocardiography test @ET) performed on 4810 pts 
wen prospectively cokcted from 31 echocardiographic laboratories. 
All pts were studied for known or suspected coronary artery disease; 
1181 early (cl8 days) after an acute myocardial infarction; 223 had 
unstable angina. The dipyridamole infusion protocol was: 0.56 mg/Kg 
over 4’ (low dose), followed by 4’ of no dose and, if still negative for 
echocardiographically assessed myocardial ischemia, 0.28 mg/Kg 
over 2’. Major adverse reactions occurred in 5 cases (0.08%). There 
were 3 cases of severe bradycardia progressing to cardiac asystole 
(one of them was aminophylline resistant, prolonged and complicated 
by an acute myocardial infarction and coma, which evolved to death 
after 23 days), 1 pulmonary edema, 1 sustained ventricular 
tachycardia. In other 20 DET studies the high dose was not given in 
spite of the echocardiographic negativity, for limiting side effects due 
to the lower dose: hypotension and bradycardia (13 pts), excessive 
tachycardia (2), headache (2), restlessness (1). vomiting (l), acute 
bronchospasm (1). In all cases, side effects promptly subsided after 
aminophylline. 
Thus, high dose DET is reasonably safe and well tolerated, even early 
after an acute myocardial infarction and in pts with unstable angina, 
when selectively applied in those pcs in whom the lower dose did not 
induce echocardiographic signs of ischemia or limiting side effects. 
